OpenAI has introduced new usage analytics and spend controls for ChatGPT Enterprise, enabling organizations to monitor AI costs in real time and set spending limits across teams and projects. The feature addresses a growing pain point for large enterprises deploying AI at scale: the inability to track departmental usage or prevent runaway costs from experimental deployments. As organizations pilot AI tools across multiple business units, visibility gaps have created significant budget risk—shadow AI spending, uncapped API calls, and unmanaged training experiments can silently inflate costs. The new controls allow enterprises to allocate budgets by team, set hard spending caps, and view detailed breakdowns of usage patterns, effectively transforming what was previously a black box into a managed cost center. This move signals that OpenAI recognizes cost governance as a prerequisite for enterprise adoption at scale.
Simultaneously, OpenAI is aggressively targeting the life sciences sector with applications that demonstrate clinical utility beyond marketing promises. GPT-5.5 Instant has been enhanced specifically for health and wellness reasoning with physician-informed evaluations, while researchers using OpenAI's reasoning models identified 18 new genetic disease diagnoses in previously unsolved pediatric cases—a concrete outcome that resonates with regulated industries. OpenAI and partner Molecule.one also demonstrated a near-autonomous AI chemist using GPT-5.4 that improved challenging drug-synthesis reactions, suggesting tangible value in medicinal chemistry workflows. To validate these capabilities, OpenAI introduced LifeSciBench, an expert-authored benchmark for evaluating AI systems on real-world life science research tasks and decisions. Unlike general benchmarks, LifeSciBench tests domain-specific reasoning, context handling, and decision-making standards that matter to researchers and regulators—essentially providing evidence that OpenAI models meet domain expectations rather than just general intelligence metrics.
The dual strategy reveals OpenAI's calculated approach to regulated industries: first establish cost transparency so enterprises feel safe scaling deployment, then prove clinical or research value to justify adoption in high-stakes environments where accuracy directly impacts human outcomes. Life sciences offers particular advantages as a wedge market—high regulatory scrutiny creates defensibility moats against competitors, specialized domain requirements justify premium pricing, and measurable outcomes (diagnoses made, reactions improved) provide auditable proof of performance. By addressing cost concerns and simultaneously demonstrating domain-specific utility, OpenAI is removing two major adoption barriers for enterprises considering large-scale AI deployment in regulated sectors.